Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + tetrahydrocannabinol (Canntab Therapeutics Limited)
- Development stage
- Phase 3
- Lead developer
- Canntab Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Canntab IR CBD:THC 5:1 tablet is an instant-release oral tablet formulation containing a 5:1 ratio of cannabidiol (CBD) and tetrahydrocannabinol (THC). Developed by Canntab Therapeutics, this pharmaceutical-grade hard pill is designed to provide precise, standardized dosing of cannabinoids for patients who require a modest amount of THC alongside a higher dose of CBD. The formulation utilizes Canntab's proprietary tableting technology to offer enhanced stability and bioavailability compared to traditional gel caps or oils. It is intended for the management of conditions such as pain, anxiety, and other indications where cannabinoid therapy is beneficial.
- Brand names
- Instacann
- Other names
- Canntab IR CBD:THC 5:1 tabletCBD:THC 5:1 tabletInstant Release CBD:THC 5:1 tablet
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on cannabidiol + tetrahydrocannabinol (Canntab Therapeutics Limited).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + tetrahydrocannabinol (Canntab Therapeutics Limited).